Zura Bio Limited (ZURA)
Zura Bio Statistics
Share Statistics
Zura Bio has 65.29M shares outstanding. The number of shares has increased by 51.52% in one year.
| Shares Outstanding | 65.29M |
| Shares Change (YoY) | 51.52% |
| Shares Change (QoQ) | 2.38% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 44.26M |
| Failed to Deliver (FTD) Shares | 4.56K |
| FTD / Avg. Volume | 0.89% |
Short Selling Information
The latest short interest is 4.99M, so 7.64% of the outstanding shares have been sold short.
| Short Interest | 4.99M |
| Short % of Shares Out | 7.64% |
| Short % of Float | 10.6% |
| Short Ratio (days to cover) | 8.08 |
Valuation Ratios
The PE ratio is -2.38 and the forward PE ratio is -2.2. Zura Bio's PEG ratio is 0.
| PE Ratio | -2.38 |
| Forward PE | -2.2 |
| PS Ratio | 0 |
| Forward PS | 3.4 |
| PB Ratio | 2.42 |
| P/FCF Ratio | -6.24 |
| PEG Ratio | 0 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Zura Bio Limited.
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.97, with a Debt / Equity ratio of 0.
| Current Ratio | 4.97 |
| Quick Ratio | 4.97 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -1.02% and return on capital (ROIC) is -78.48%.
| Return on Equity (ROE) | -1.02% |
| Return on Assets (ROA) | -0.6% |
| Return on Capital (ROIC) | -78.48% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -4.31M |
| Employee Count | 14 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -203K |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -62.94% in the last 52 weeks. The beta is -0.01, so Zura Bio's price volatility has been lower than the market average.
| Beta | -0.01 |
| 52-Week Price Change | -62.94% |
| 50-Day Moving Average | 1.89 |
| 200-Day Moving Average | 3.41 |
| Relative Strength Index (RSI) | 37.85 |
| Average Volume (20 Days) | 510.41K |
Income Statement
| Revenue | n/a |
| Gross Profit | 0 |
| Operating Income | -62.64M |
| Net Income | -60.36M |
| EBITDA | -60.56M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -2.09 |
Balance Sheet
The company has 99.81M in cash and 0 in debt, giving a net cash position of 99.81M.
| Cash & Cash Equivalents | 99.81M |
| Total Debt | 0 |
| Net Cash | 99.81M |
| Retained Earnings | -103.49M |
| Total Assets | 189.07M |
| Working Capital | 170.73M |
Cash Flow
In the last 12 months, operating cash flow was -15.05M and capital expenditures -8M, giving a free cash flow of -23.05M.
| Operating Cash Flow | -15.05M |
| Capital Expenditures | -8M |
| Free Cash Flow | -23.05M |
| FCF Per Share | -0.7 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
ZURA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -153.68% |
| FCF Yield | -25.96% |
Analyst Forecast
The average price target for ZURA is $15, which is 1002.9% higher than the current price. The consensus rating is "Buy".
| Price Target | $15 |
| Price Target Difference | 1002.9% |
| Analyst Consensus | Buy |
| Analyst Count | 6 |
Scores
| Altman Z-Score | 1.9 |
| Piotroski F-Score | 2 |